The BRAF V600E mutation enhances the diagnostic accuracy of FNAB for AUS nodules. Combining FNAB with BRAF V600E testing improves the detection rate of PTC, increasing the sensitivity and specificity of the diagnostic process [30,31]. This combined approach is particularly useful in stratifying the risk of malignancy in indeterminate thyroid nodules, allowing for more precise management decisions. The gene discussed is BRAF; the disease is thyroid nodule.